Financial News

Financial Report: BASi

Bioanalytical revenue down 35% in the quarter

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

BASi 3Q Revenues: $5.1 million (-18%) 3Q Loss: $433K (earnings were $1.5 million 3Q15) YTD Revenues: $15.3 million (-14%) YTD Loss: $1.3 million (earnings were $1.8 million YTD15) Comments: Bioanalytical revenue was down 35%, due to fewer samples received and analyzed in the quarter. Product segment increased 11% to $1,280,000, driven by instrument sales from BASi Culex automated in-vivo sampling line, plus an increase in sales of analytical instruments and consumables. The compan...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters